Introduction In the fast-paced world of cancer treatment, Imdelltra (tarlatamab-DLE) is emerging as a groundbreaking immunotherapy. Approved by the FDA for patients with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after platinum-based chemotherapy, Imdelltra offers a new lifeline. However, beyond the clinical data, there is an essential operational aspect – the Imdelltra J …
Introduction Obinutuzumab, marketed as Gazyva in the United States and Gazyvaro in Europe, represents a major advancement in targeted cancer therapy. It’s a humanized monoclonal antibody designed to recognize and attack the CD20 antigen present on B lymphocytes. This mechanism makes it highly effective in treating Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL)—two common …
Introduction Pembrolizumab, marketed under the brand name Keytruda, is an advanced immunotherapy drug that has revolutionized cancer treatment. It works by helping the immune system to more effectively recognize and destroy cancer cells. Pembrolizumab has improved survival outcomes for many cancer patients, but it is extremely important to understand the side effects of pembrolizumab before …
Highlights What Is Imlunestrant? Imlunstrant , marketed under the brand name Inlurio, is an oral selective estrogen receptor degrader (SERD) developed by Eli Lilly & Company. It is a next-generation endocrine therapy specifically designed for postmenopausal women and men with ER-positive, HER2-negative breast cancer that harbors ESR1 mutations. Unlike older SERDs that require injections, Imlunstrant …
Introduction On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (brand name: Lynozyfic) for the treatment of adults with relapsed or refractory multiple myeloma (R/R MM) who have received at least four prior lines of therapy. This linvoseltamab FDA approval represents a major milestone in oncology, especially for …
Introduction On August 6, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (brand name: Modeyso), making history as the first systemic therapy for patients with diffuse midline glioma (DMG) harboring the H3 K27M mutation. This approval is a landmark moment, offering hope for children and adults battling this devastating and …
Introduction The U.S. Food and Drug Administration (FDA) granted accelerated approval to Zongertinib (brand name Hernexeos) on August 8, 2025, marking a significant milestone in lung cancer treatment. Zongertinib is approved for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and …
Introduction Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Accurate diagnosis and staging are crucial for choosing the right treatment plan and improving patient outcomes. Conventional imaging methods often fall short of detecting small or early lesions, especially in cases of recurrence. This is where Gozellix® comes in. After radiolabeling …
Bone health is one of the most important aspects of cancer treatment, especially for people whose disease has spread to the skeleton. Older cancer patients often face painful and dangerous bone complications, such as fractures, spinal cord compression, and bone lesions that require radiation or surgery. Bomyntra is a newly approved treatment designed to prevent …
Introduction On February 14, 2025, the US Food and Drug Administration (FDA) approved vimseltinib, marketed under the brand name Romvimza™, for the treatment of tenosynovial giant cell tumor (TGCT) in adult patients. This is a significant advance for patients struggling with this rare, debilitating joint condition. Known as a switch-control kinase inhibitor of the colony-stimulating …
